How can you say that when Mayo controls the clinics, the trials, the patients, the procedures, the results and the analysis? Mayo has had their hold lifted for the use of Imetelstat. It is obvious that Mayo is in control. That does not mean that they own Imetelstat, but they have an extreme invested interest that must be honored by Geron.
It appears that Imetelstat is NOT a "one-trick-pony". Mayo Clinic and Geron are putting together a network of researchers that include clinical trials and universities in the USA and abroad. This is a vast undertaking that will eventually "explode" with positive news on several fronts. Mayo is playing a game of poker (Mayo brochure, Yale, Israel, etc.), that, for now, is very conservative and quiet.
The FDA is in Mayo's pocket, to be used, when they see fit. Mayo took a test drug with possibilities (animal studies) from Geron, and made it into a human reality. For that they get to control and lead. Geron benefits from Mayo's leadership and good judgment.
What is the resolution and conclusion? As far as I can tell there are no meaningful side-effects that are related to the liver. Mayo has had their hold lifted, which means that the FDA is no longer concerned about this matter. That means that the MF trials are in the clear, and that should carry over to all blood cancers. Geron's hold seems to be a mystery, and may be related to corporate short-comings, that have nothing to do with science and medicine.
More About Liver Side-effects (not serious or dangerous). Further comments would be appreciated.
From:Van-Pic***** "Grade 3,4,5 liver enzyme elevation is reversible by dose control (needless to say, this has been stated numerous times) but..when it comes to the reversibility of 'Persistent' low level hepatotoxicity...well in that case we still don't know. The hold was lifted in mayo's MF IST so I assume Dr T gave FDA what they wanted but it's not official yet and in geron's case(ET,PV,MM) the jury is still out." *****
I thought the liver "confusion" side-effects was completely resolved in Mayo's favor. Imetestat is relatively safe drug for MF or other blood cancers. There are no meaningful liver side effects. Imetelstat, at this point in time, is a joint Mayo-Geron marriage. Mayo's success is Geron's success. Does anyone think differently?
Clearly all small biotechs are not created the same. Geron is a gem at these prices.
There is nothing overpriced about Geron. Mayo Clinic has been rated the #1 health institution in the USA, and is fully behind Imetelstat. Imetelstat works and is safe. Why the stock price is controlled at such a low level is a mystery, but one day the explosion will happen (as stated by Seeking Alpha and others).
This $3 close shows that market manipulators have more control over Geron's stock price than Mayo's solid successes.
The hold for continuing the Mayo trials (MF) has been lifted, but Geron's hold is still in place. Geron is treated as a 2nd class citizen. Mayo is the key, and Geron benefits from Mayo's progress.
We shall see. The FDA should be finished with Mayo, as far as holds go. Some have thought that the FDA has some special issues with Geron, so their holds are less transparent . The FDA definitely trusts Mayo, but may find Geron somewhat unstable, and in need of additional supervision. Geron is fortunate to have such a stalwart leading the research in the trials, and the formalities with the FDA. Mayo is now going totally public with Imetelstat (medical public, big pharma public, investment public, global public) with the brochure. There is whispering-in-the-wind.
There is a tug-of-war going on. On one side are market forces that work off of charts and technical considerations; on the other side are Mayo Clinic's forces (trials, science, medicine, successes).
Mayo rates Imetelstat in the exceptional category. That is a fact. No one knows how to translate that into Geron's stock price. One would think that the conversion factor would be very high, because Imelelstat is unique, effective and safe.
Buy 1000 shares now, if you only have a casual interest. You will not regret it. For serious investors, anything under $5 is a very good price. The potential is unknown, but appears to be substantial.
This confirms what many suspected, but were not confident enough to invest in Geron until now. Geron is as close to a sure winner as you can get, and is a prize for one of the large pharmas to win.
bb###---No matter what you "conjecture", people are being saved from starvation, and genetics is the future of all biology (plant & animal). Monsanto may not get everything right, but they are a power force for a better world.
Black###---I think we are both saying that Geron is not master of its own future, primarily because of the success of Imetelstat, and policies that are now being formed by Mayo and the FDA. This is price that Geron must pay for its future, and it could work out for them. I'm holding on to my stock because I believe in a good outcome for Imetelstat, no matter what the eventual corporate and medical research structure becomes.
Mayo must experiment with many techniques and medicines, with Imetelstat being one of the major successes (many must fail). I wonder, how much of a say, Mayo has in the future of Imetelstat. After all, if Imetelstat fails, so does Geron. I am guessing that Imetelstat will be divided into 3 parts: Geron, Mayo, New partner, so that all will benefit.
This could explain some of Geron's management's confusion. Scarlett was brought on board to sell this company with questionable and risky assets. Imetelstat & Mayo came threw in a stellar way, and now no one quite knows what Geron is worth ($5, $10, $50, $100 ???). Geron is faced with new questions of going it alone, choosing a partner, or selling the company (the original plan). Mayo looks like they are bringing bright and new opportunities to Geron. Scarlett is thinking very hard about the possibilities. Time is on Geron's side, and that of long term investors.